NO760993L - - Google Patents
Info
- Publication number
- NO760993L NO760993L NO760993A NO760993A NO760993L NO 760993 L NO760993 L NO 760993L NO 760993 A NO760993 A NO 760993A NO 760993 A NO760993 A NO 760993A NO 760993 L NO760993 L NO 760993L
- Authority
- NO
- Norway
- Prior art keywords
- radical
- formula
- compound
- alkyl
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB11644/75A GB1502312A (en) | 1975-03-20 | 1975-03-20 | Quinolone derivatives |
| GB4204375 | 1975-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO760993L true NO760993L (OSRAM) | 1976-09-21 |
Family
ID=26248416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO760993A NO760993L (OSRAM) | 1975-03-20 | 1976-03-19 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4066651A (OSRAM) |
| JP (1) | JPS51118773A (OSRAM) |
| AU (1) | AU1147676A (OSRAM) |
| CS (1) | CS188273B2 (OSRAM) |
| DD (1) | DD124117A5 (OSRAM) |
| DE (1) | DE2611824A1 (OSRAM) |
| DK (1) | DK115376A (OSRAM) |
| ES (1) | ES446234A1 (OSRAM) |
| FI (1) | FI760729A7 (OSRAM) |
| FR (1) | FR2304342A1 (OSRAM) |
| HU (1) | HU172032B (OSRAM) |
| IE (1) | IE43079B1 (OSRAM) |
| IL (1) | IL49126A0 (OSRAM) |
| LU (1) | LU74594A1 (OSRAM) |
| NL (1) | NL7602834A (OSRAM) |
| NO (1) | NO760993L (OSRAM) |
| PT (1) | PT64921B (OSRAM) |
| SE (1) | SE434394B (OSRAM) |
| SU (1) | SU648090A3 (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE47592B1 (en) * | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
| US5225402A (en) * | 1989-02-10 | 1993-07-06 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| ES2056259T3 (es) * | 1989-02-10 | 1994-10-01 | Otsuka Pharma Co Ltd | Derivados de carboestirilo. |
| AU8665991A (en) * | 1990-09-07 | 1992-03-30 | Schering Corporation | Antiviral compounds and antihypertensive compounds |
| CA2066104C (en) * | 1991-04-19 | 2003-05-27 | Hidenori Ogawa | Benzazepine derivatives as vasopressin antagonists |
| CA2088582A1 (en) * | 1991-06-07 | 1992-12-08 | Katsuya Yamasaki | Anti-diabetes mellitus |
| DE19839499A1 (de) * | 1998-08-29 | 2000-03-02 | Merck Patent Gmbh | 2-Oxo-2H-chinolinderivate |
| WO2001016133A2 (en) | 1999-08-27 | 2001-03-08 | Ligand Pharmaceuticals Incorporated | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| WO2001016139A1 (en) * | 1999-08-27 | 2001-03-08 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| AU7586600A (en) | 1999-09-14 | 2001-04-17 | Ligand Pharmaceuticals Incorporated | Rxr modulators with improved pharmacologic profile |
| FR2811912B1 (fr) * | 2000-07-21 | 2003-02-07 | Gattefosse Ets Sa | Procede d'enrobage de particules solides par un agent thermofusible, et particules solides ainsi enrobees |
| MXPA06001751A (es) * | 2003-08-22 | 2006-05-12 | Ligand Pharm Inc | Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno. |
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| AR059898A1 (es) * | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| ES2365966T3 (es) | 2007-09-14 | 2011-10-14 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disustituidas. |
| ES2409215T3 (es) * | 2007-09-14 | 2013-06-25 | Janssen Pharmaceuticals, Inc. | 4-fenil-1H-piridin-2-onas 1-3-disustituidas |
| TWI445532B (zh) * | 2007-09-14 | 2014-07-21 | Janssen Pharmaceuticals Inc | １’，３’－二取代－４－苯基－３，４，５，６－四氫－２ｈ，１’ｈ－〔１，４’〕聯吡啶基－２’－酮化物 |
| CA2704436C (en) * | 2007-11-14 | 2016-01-05 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| WO2009062309A1 (en) * | 2007-11-15 | 2009-05-22 | Universite Laval | Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof |
| US8691849B2 (en) | 2008-09-02 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| CN102186477B (zh) | 2008-10-16 | 2013-07-17 | 奥梅-杨森制药有限公司 | 作为代谢型谷氨酸受体调节剂的吲哚和苯并吗啉衍生物 |
| CN102232074B (zh) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物 |
| ES2409006T3 (es) | 2009-05-12 | 2013-06-24 | Janssen Pharmaceuticals Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de los receptores mGluR2 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| EP2430022B1 (en) | 2009-05-12 | 2013-11-20 | Janssen Pharmaceuticals, Inc. | 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| JP5852665B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| AU2011328194B2 (en) | 2010-11-08 | 2015-04-16 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| WO2012062759A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| LT3096790T (lt) | 2014-01-21 | 2019-10-10 | Janssen Pharmaceutica, N.V. | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
| UA127921C2 (uk) | 2014-01-21 | 2024-02-14 | Янссен Фармацевтика Нв | Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3772301A (en) * | 1971-11-22 | 1973-11-13 | Warner Lambert Co | (4-substituted)4-(methylsulfinyl)methylcarbostyrils |
-
1976
- 1976-02-23 IE IE352/76A patent/IE43079B1/en unknown
- 1976-02-25 SE SE7602339A patent/SE434394B/xx not_active IP Right Cessation
- 1976-02-27 AU AU11476/76A patent/AU1147676A/en not_active Expired
- 1976-03-01 US US05/662,685 patent/US4066651A/en not_active Expired - Lifetime
- 1976-03-01 IL IL49126A patent/IL49126A0/xx unknown
- 1976-03-17 DK DK115376A patent/DK115376A/da unknown
- 1976-03-18 LU LU74594A patent/LU74594A1/xx unknown
- 1976-03-18 FI FI760729A patent/FI760729A7/fi not_active Application Discontinuation
- 1976-03-18 NL NL7602834A patent/NL7602834A/xx not_active Application Discontinuation
- 1976-03-18 DD DD191915A patent/DD124117A5/xx unknown
- 1976-03-19 FR FR7608061A patent/FR2304342A1/fr active Granted
- 1976-03-19 CS CS761804A patent/CS188273B2/cs unknown
- 1976-03-19 NO NO760993A patent/NO760993L/no unknown
- 1976-03-19 SU SU762337250A patent/SU648090A3/ru active
- 1976-03-19 PT PT64921A patent/PT64921B/pt unknown
- 1976-03-19 DE DE19762611824 patent/DE2611824A1/de active Granted
- 1976-03-19 HU HU76IE00000737A patent/HU172032B/hu unknown
- 1976-03-20 ES ES446234A patent/ES446234A1/es not_active Expired
- 1976-03-22 JP JP51031184A patent/JPS51118773A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| NL7602834A (nl) | 1976-09-22 |
| CS188273B2 (en) | 1979-02-28 |
| PT64921A (en) | 1976-04-01 |
| FR2304342A1 (fr) | 1976-10-15 |
| JPS51118773A (en) | 1976-10-18 |
| FI760729A7 (OSRAM) | 1976-09-21 |
| SU648090A3 (ru) | 1979-02-15 |
| ES446234A1 (es) | 1977-10-01 |
| IE43079L (en) | 1976-09-20 |
| DE2611824A1 (de) | 1976-09-30 |
| DK115376A (da) | 1976-09-21 |
| IL49126A0 (en) | 1976-05-31 |
| AU1147676A (en) | 1977-09-01 |
| SE7602339L (sv) | 1976-09-21 |
| IE43079B1 (en) | 1980-12-17 |
| DE2611824C2 (OSRAM) | 1987-06-19 |
| US4066651A (en) | 1978-01-03 |
| PT64921B (en) | 1977-08-24 |
| LU74594A1 (OSRAM) | 1977-05-06 |
| DD124117A5 (OSRAM) | 1977-02-02 |
| HU172032B (hu) | 1978-05-28 |
| SE434394B (sv) | 1984-07-23 |
| JPH0122267B2 (OSRAM) | 1989-04-25 |
| FR2304342B1 (OSRAM) | 1979-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO760993L (OSRAM) | ||
| NO174506B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser | |
| NO164476B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk virksomme 1,2,3,5-tetrahydroimidazo-(2,1-b)-kinazoliner. | |
| CS228536B2 (en) | Production method of 3-aryl-5-isothiazole | |
| DK162524B (da) | Analogifremgangsmaade til fremstilling af 5-alkylthio-tetrazolderivater | |
| IL42799A (en) | Carbazolic history of alcohols, sites and alkanoic acids, their preparation and pharmaceutical preparations containing signal | |
| NO881411L (no) | Substituerte pyrroler. | |
| US4362875A (en) | Process for preparing (1-acylaminomethyl)-1,2,3,4-tetrahydroisoquinolines | |
| IE852703L (en) | Oxindole antiinflammatory agents. | |
| MX2012005189A (es) | Inhibidores de ire-1-alfa. | |
| Szmuszkovicz | 3-Acylindole mannich bases and their transformation products | |
| NO126370B (OSRAM) | ||
| LT3675B (en) | Indenoindole copounds ii, process for preraring them and pharmaceutical composition containing them | |
| NO163597B (no) | Styreinnretning for et ett-eller tosporet kjoeretoey. | |
| NO142346B (no) | Analogifremgangsmaate til fremstilling av nye terapeutisk aktive kondenserte n-fenylsubstituerte pyrroler | |
| NO169648B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive arakidonsyre-derivater | |
| NO803693L (no) | 2,3-indoldion-derivater. | |
| IE55377B1 (en) | 1,5-diphenylpyrazolin-3-one compounds,method for preparing them,and pharmaceutical compositions containing these compounds | |
| NO131930B (OSRAM) | ||
| Jacobs et al. | 4-Substituted Cinnoline Derivatives1 | |
| US4420476A (en) | Benzofuro[3,2-c]pyrazol-3-amine derivatives | |
| US4138490A (en) | Analgesic compositions containing 1,2-dihydro-2-oxoquinol-4-ylpropionic acid derivatives | |
| Unangst et al. | 2‐Indolyl ketone synthesis | |
| DK150158B (da) | Analogifremgangsmaade til fremstilling af 4-phenylthieno-(2,3-c)piperidiner eller fysiologisk acceptable syreadditionssalte deraf | |
| US3946019A (en) | 7H-Indolizino [5,6,7-IJ]isoquinoline derivatives |